What they say: Introduction:
A recent study from the Department of Genetics, Paul F. Glenn Laboratories for the Biological Mechanisms of Aging Harvard Medical School, Boston,USA; and Department of Pharmacology, School of Medicine, The University of New South Wales, Australia shows that Sirtuin-2 induces the checkpoint kinase BubR1 to increase lifespan. This study was published, in the 1 July 2014 issue of the journal “EMBO”, by Prof Sinclair, North BJ, and others.
What we say:
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Natural product-based Lifespan extension therapy: A pharmaceutical mixture encompassing Chrysin and α-linoleic acid increases life span via up-regulation of its target gene BubR1
What is known?
Both Hesperidin and Naringenin have been shown to possess anti-hyperglycemic property. However, the exact mechanism of action is far from clear. I had published earlier that Hesperidin and Naringenin, individually, may improve insulin sensitivity, promote resistance to bone, immune and motor dysfunction and extend lifespan through down regulation of p70 S6 Kinase.
From research findings to therapeutic opportunity:
This study suggests provides mechanistic insights into how a therapeutic mix encompassing Chrysin and α-linoleic acid may promote lifespan extension. Chrysin and α-linoleic acid, by increasing the expression of their target gene, they may: (a) increase the expression of BuBR1; (b) decrease the expression of p70 S6 Kinase; and (c) regulate the expression of a number of longevity-promoting molecules (Fig. 1).
[easy_payment currency=”USD”]
Figure 1. A therapeutic mix encompassing Chrysin and α-linoleic acid may extend mammalian life span via up regulation of BuBR1 and down regulation of p70 S6 Kinase
Figure 2. The chemical structure of Chrysin and α-linoleic acid and the source from it can be derived is indicated above.
Thereby, they may: (1) increase insulin sensitivity; (2) attenuate cognitive impairment; (3) delay diseases of aging; (4) slow down cardiac aging; (5) promote resistance to bone, immune and motor dysfunction; (6) promote tissue rejuvenation; and (7) prolong median life span. Thus, pharmacological formulations encompassing “Chrysin and α-linoleic acid or their analogues, either alone or in combination with other drugs” may be used to extend the lifespan of an individual (fig. 1).
Details on the research findings:
Idea Proposed/Formulated (with experimental evidence) by:
Dr L Boominathan Ph.D.
Amount: $500#
Undisclosed mechanistic information: How a therapeutic mix encompassing Chrysin and α-linoleic acid increases the expression of BubR1 and extends mammalian life-span
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
# Research cooperation
References:
Web: http://genomediscovery.org or http://newbioideas.com
Citation: Boominathan, L., Natural product-based Lifespan extension therapy: A pharmaceutical mixture encompassing Chrysin and α-linoleic acid increases life span via up-regulation of its target gene BubR1, 1/January/2018, 9.01 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at admin@genomediscovery.org